Pfizer today announces its intention to consolidate active ingredient manufacturing for key medicines manufactured in Ireland. It proposes that products manufactured at the Little Island site will relocate to the Ringaskiddy site during 2014. This is part of its global efforts to better align manufacturing capacity in response to reducing volumes following patent expiration of... Read More